Everolimus, an mTOR inhibitor, has received approval for the treatment of subependymal giant cell astrocytoma (SEGA), and is being investigated in combination with other drugs such as temozolomide, lenvatinib (a VEGFR inhibitor), sorafenib, ribociclib (a CDK inhibitor), and dasatinib (a BCR/ABL and SRC inhibitor). The gene discussed is SRC; the disease is subependymal giant cell astrocytoma.